Jason Bryant’s Post

Latest update on our range of insights focused capabilities right here!

🚀 Attention Market Access Executives in Biopharma! 🌟 Are you grappling with time-consuming data workflows that hinder your ability to drive successful Market Access strategies? It's time to unlock new possibilities by harnessing advanced evidence generation capabilities to streamline processes, save resources, and accelerate evidence-based decision-making. 📊💡 **Challenges:** 1. **Pricing and Reimbursement Data Analysis:** Analyzing pricing and reimbursement data from diverse sources can be a daunting task for Market Access Executives. The complexity of evaluating pricing structures, reimbursement policies, and market access barriers often leads to prolonged data analysis processes and delays in strategy development. 💸⏳ 2. **Real-World Evidence Synthesis:** Incorporating real-world evidence (RWE) into Market Access strategies is essential but can pose challenges in terms of data collection, synthesis, and interpretation. Extracting meaningful insights from RWE sources requires meticulous attention to detail and significant time investment, slowing down decision-making processes. 🌍🔍 3. **Value Proposition Development:** Crafting a compelling value proposition based on robust evidence is vital for successful Market Access initiatives. However, the process of gathering, analyzing, and presenting value evidence can be labor-intensive and time-consuming, impacting the speed at which strategies are developed and implemented. 💼📈 **Solution:** Embracing advanced evidence generation capabilities can empower Market Access Executives to overcome these challenges and drive efficiencies in data workflows. Here's how: 1. **Advanced Data Analytics and Visualization Tools:** By leveraging advanced data analytics and visualization tools, Market Access teams can streamline pricing and reimbursement data analysis. These tools offer dynamic insights into pricing trends, reimbursement landscapes, and market access dynamics, enabling executives to make informed decisions faster and more effectively. 📈💻 2. **Machine Learning for RWE Synthesis:** Incorporating machine learning algorithms for real-world evidence synthesis can revolutionize the way Market Access Executives extract insights from disparate sources. These algorithms can automate data extraction, standardization, and synthesis processes, reducing the time required to derive meaningful RWE insights and enhancing decision-making capabilities. 🤖📊 3. **Value Evidence Modeling Platforms:** Utilizing value evidence modeling platforms can expedite the development of compelling value propositions. These platforms offer customizable frameworks for analyzing cost-effectiveness, budget impact, and other value components, enabling Market Access Executives to create persuasive value messages efficiently and effectively. 💡💰 #evidencegeneration #biopharma #marketaccess

Pharma leaders know they need to make their data warehouses more patient-centric but sometimes struggle to transform traditional HCP-centric data warehouses. Here are four keys to building patient-centric data warehouses: https://lnkd.in/g_wdN4Qb

🚀 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐋𝐞𝐯𝐞𝐥 𝐔𝐩 𝐘𝐨𝐮𝐫 𝐃𝐚𝐭𝐚 𝐆𝐚𝐦𝐞? 📊 If diving into data insights is your thing, you can’t miss this! 👇 🔎 𝐀𝐠𝐠𝐫𝐞𝐠𝐚𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 Ever wondered how to extract those wow insights from a sea of data? 💡 Join us on Oct 26th for an action-packed session where we’ll unpack the magic behind aggregate reporting. 🗓 𝐃𝐚𝐭𝐞 & 𝐓𝐢𝐦𝐞: 📅 Oct 26th, 2024, Saturday 🕣 08:30 PM IST (India) 🕒 11:00 AM GMT-4 (USA/Canada) 🕓 04:00 PM EST (UK) 💥 𝐖𝐡𝐚𝐭 𝐭𝐨 𝐄𝐱𝐩𝐞𝐜𝐭? 🛠️ Interactive Exercises: Sharpen your reporting skills. 🧑🏫 Expert Insights: Learn from industry pros. 🖥️ Advanced Tools: Explore top data aggregation tools. ❓ Live Q&A: Get real-time answers! 🎯 𝐖𝐡𝐨 𝐒𝐡𝐨𝐮𝐥𝐝 𝐀𝐭𝐭𝐞𝐧𝐝? Pharmaceutical experts 🧑⚕️, doctors 👩⚕️, drug safety physicians 💊, and specialists in ICSR & case processing 📋 looking to level up their data aggregation techniques. Let’s make data work smarter, not harder! 💡 🔗 Save Your Spot Now! 👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐇𝐞𝐫𝐞: https://lnkd.in/g5AJ8TtB 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐭𝐮𝐫𝐧 𝐲𝐨𝐮𝐫 𝐝𝐚𝐭𝐚 𝐢𝐧𝐭𝐨 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬? 𝐒𝐞𝐞 𝐲𝐨𝐮 𝐭𝐡𝐞𝐫𝐞! 🙌 #DataScience #Pharmacovigilance #DataAnalytics #AggregateReporting #PharmaIndustry #DrugSafety #ICSR #MedicalData #DataDriven #Workshop2024 #PharmaExperts #DataInsights #HealthTech #AIInPharma #BigData #DataInnovation #DataVisualization #HealthcareAnalytics

Pharma market trends with Open Data Blend! Access England's prescribing data with Open Data Blend – your go-to resource for uncovering actionable insights in the Pharma market. Why choose Open Data Blend Datasets? ✅ Optimised for Analytics: Accelerate your workflows with streamlined data. ✅ Insightful Enrichments: Access cleansed, enriched columns for deeper insights. ✅ Versioned Data: Ensure reproducibility with version-controlled datasets. ✅ Timely Updates: Stay ahead with up-to-date, reliable data. Transform your market research into actionable strategies. Start uncovering trends today: https://lnkd.in/e4w9UtTr #Pharma #OpenData #MarketResearch #AnalyticsMadeEasy

$12B Write-Off 😱 : A Case for Smarter Pharma Data Strategy—Enough with Excel Already! 😡 ... ... ... Amgen recently faced a staggering $12 billion market cap 💰 hit due to an overlooked Excel tab🤯. Yes, you read that right—an unreviewed Excel tab containing critical data on bone density changes in patients treated with their obesity drug, MariTide. This isn’t just a story about one mistake; it’s a wake-up call for the entire industry. In drug R&D, data isn’t just a byproduct—it’s the backbone of every decision we make. And when that data isn’t properly managed, stored, shared, and analyzed, the consequences can be catastrophic, both for patients and shareholders. What can we learn from this? 📊 Collecting data isn’t enough. It’s time to embrace FAIR principles—making data Findable, Accessible, Interoperable, and Reusable—right at the source of production. 🤝 Transparency is non-negotiable. Proper dissemination of critical information ensures teams have the insights they need to make informed decisions - Clearly Excel is not the right tool for the job!!! 🚀 Data strategy is a growth engine, not an expense. With the right frameworks in place, companies can avoid costly mistakes while accelerating drug development and de-risking R&D. The real value of data lies in how we use it to drive innovation, avoid pitfalls, and ultimately deliver better treatments to patients faster. ___________ Love ❤️ this post? Add your comments 💭, re-share ♻ it with your network, follow me 🔔 for more posts like this, and DM me 📩 if you want to deep dive on this topic!

"Wow—🤖 🧠 Thibault GEOUI 🧬 💊 what a powerful wake-up call for the entire industry! This $12B write-off isn’t just about a single oversight; it’s a stark reminder that legacy tools like Excel, while familiar, are ill-equipped to handle the complexity and criticality of modern pharma data. The call for FAIR principles is spot on—data isn’t just a byproduct of R&D; it is the R&D. But beyond just making data accessible, shouldn’t we also be challenging how we foster accountability and collaboration across teams? Transparency and real-time integration shouldn’t be aspirational—they should be standard operating procedures. The real question is: why are we still using tools that don’t evolve with the stakes? What other blind spots are we missing because of outdated systems? Let’s prioritize data strategies that treat information as the lifeblood of innovation—because patients (and shareholders) can’t afford another $12B mistake. 👏". ZAETHER Michael Cody Jay Upadhyay John Seffernick Stephen Britton Philip Braun Samantha Szatek Russell Jackson Mike Shufelt Trevor Murray Michael Shepard Lesli Breault Tim Adkins Ann Morrow Sachin Suryawanshi Venkat Balakrishnan PhD Jenn Azar Roman Rodriguez Vincent. How can we prevent this from happening again and inspire our customers? #datafirst #UNS #dataasaproduct #DaaS

A thought-provoking piece by McKinsey. There are certainly significant implications for the industry, manufacturers, and patients in particular should progress be made on the collection, validity, and application of real-world data into satisfactory evidence. More life-changing medications and technologies, developed quicker and at much lower cost would be a massive leap forward. But there is much work to do in getting to that point. #realworldevidence #realworlddata #mckinsey

🚀 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐋𝐞𝐯𝐞𝐥 𝐔𝐩 𝐘𝐨𝐮𝐫 𝐃𝐚𝐭𝐚 𝐆𝐚𝐦𝐞? 📊 If diving into data insights is your thing, you can’t miss this! 👇 🔎 𝐀𝐠𝐠𝐫𝐞𝐠𝐚𝐭𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 Ever wondered how to extract those wow insights from a sea of data? 💡 Join us on Oct 5th for an action-packed session where we’ll unpack the magic behind aggregate reporting. 🗓 𝐃𝐚𝐭𝐞 & 𝐓𝐢𝐦𝐞: 📅 Oct 05th, 2024, Saturday 🕣 08:30 PM IST (India) 🕒 11:00 AM GMT-4 (USA/Canada) 🕓 04:00 PM EST (UK) 💥 𝐖𝐡𝐚𝐭 𝐭𝐨 𝐄𝐱𝐩𝐞𝐜𝐭? 🛠️ Interactive Exercises: Sharpen your reporting skills. 🧑🏫 Expert Insights: Learn from industry pros. 🖥️ Advanced Tools: Explore top data aggregation tools. ❓ Live Q&A: Get real-time answers! 🎯 𝐖𝐡𝐨 𝐒𝐡𝐨𝐮𝐥𝐝 𝐀𝐭𝐭𝐞𝐧𝐝? Pharmaceutical experts 🧑⚕️, doctors 👩⚕️, drug safety physicians 💊, and specialists in ICSR & case processing 📋 looking to level up their data aggregation techniques. Let’s make data work smarter, not harder! 💡 🔗 Save Your Spot Now! 👉 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐇𝐞𝐫𝐞: https://lnkd.in/gNHGpQFU 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐭𝐮𝐫𝐧 𝐲𝐨𝐮𝐫 𝐝𝐚𝐭𝐚 𝐢𝐧𝐭𝐨 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬? 𝐒𝐞𝐞 𝐲𝐨𝐮 𝐭𝐡𝐞𝐫𝐞! 🙌 #DataDriven #PharmaTech #DataInsights #TechInnovation #Pharmaceuticals #DrugSafety #ICSR #DataAggregation #Workshops #ProfessionalDevelopment #LiveLearning #HealthcareInnovation #ClinicalData #PharmaExperts #DataAnalytics #SafetyReporting #DataScience

Despite surveys highlighting pinpoints in the industry's mission to enhance data automation for therapy development, the industry is making significant progress. Specifically, Envision Pharma Group has witnessed how combining the right technology and skilled professionals with efficient processes can dramatically improve outcomes and operational efficiencies across the sector. As embracing data automation, with dedicated data professionals leading the charge, becomes standard practice, medical affairs teams will have greater access to complex data quicker, enabling streamlined and targeted drug development and patient care approaches. https://lnkd.in/exfM5rcM